Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056/NEJM199903113401001 European Association for the Study of the Liver. EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. Available from: http://www.easl.eu. [Accessed March 10, 2016]. American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update. Available from: http://www.aasld.org. [Accessed March 10, 2016]. European Society for Medical Oncology. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010. Available from: http://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Hepatocellular-Carcinoma. [Accessed March 10, 2016]. Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122 European Society of Digestive Oncology. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Available from: http://www.esdo.eu. [Accessed March 10, 2016]. Quirk, 2015, Management of hepatocellular carcinoma with portal vein thrombosis, World J Gastroenterol, 21, 3462, 10.3748/wjg.v21.i12.3462 Kulik, 2008, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, 47, 71, 10.1002/hep.21980 Pecorelli A. Cambiamenti epidemiologici dell’epatocarcinoma agli inizi del XXI secolo: dal ruolo emergente delle malattie dismetaboliche quali fattori eziopatogenetici, alla necessitià di revisione del sistema di stadiazione [PhD thesis, Alma Mater Studiorum–Università di Bologna. Bologna, Italy]. 2015. Colombo, 2015, Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers, Ther Clin Risk Manag, 11, 1603, 10.2147/TCRM.S88208 Sangro, 2011, European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002/hep.24451 Salem, 2011, Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 140, 497, 10.1053/j.gastro.2010.10.049 Mazzaferro, 2013, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study, Hepatology, 57, 1826, 10.1002/hep.26014 Geschwind, 2004, Yttrium-90 microspheres for the treatment of hepatocellular carcinoma, Gastroenterology, 127, S194, 10.1053/j.gastro.2004.09.034 Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget (published online ahead of print August 26, 2016). doi:10.18632/oncotarget.11644. Drummond, 2009, Economic evaluation for devices and drugs—same or different?, Value Health, 12, 402, 10.1111/j.1524-4733.2008.00476_1.x Tarricone, 2014, Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?, Expert Rev Pharmacoecon Outcomes Res, 14, 707, 10.1586/14737167.2014.950233 Motheral, 2003, A checklist for retrospective database studies—report of the ISPOR Task Force on Retrospective Databases, Value Health, 6, 90, 10.1046/j.1524-4733.2003.00242.x Rosenbaum, 1983, The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 15, 10.1093/biomet/70.1.41 Tandon, 2009, Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies, Liver Int, 29, 502, 10.1111/j.1478-3231.2008.01957.x Child, 1964, Surgery and portal hypertension, Major Probl Clin Surg, 1, 1 Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Available from: http://EconPapers.repec.org/RePEc:boc:bocode:s432001. [Accessed March 10, 2016]. Eddy, 2012, Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7, Value Health, 15, 843, 10.1016/j.jval.2012.04.012 National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. Available from: http://publications.nice.org.uk/pmg9. [Accessed March 10, 2016]. Bolondi, 2013, Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma, Dig Liver Dis, 45, 712, 10.1016/j.dld.2013.01.012 Cammà, 2013, Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C, J Hepatol, 59, 658, 10.1016/j.jhep.2013.05.019 CEA Registry. Available from: https://research.tufts-nemc.org/cear4/SearchingtheCEARegistry. [Accessed March 10, 2016]. Hulstaert, 2013, Should chronic hepatitis B be treated as early as possible?, Int J Technol Assess Health Care, 29, 35, 10.1017/S0266462312000736 Tanaka, 2012, Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography, Hepatol Res, 42, 376, 10.1111/j.1872-034X.2011.00936.x Liu, 2011, Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients, PLoS One, 6, e26783, 10.1371/journal.pone.0026783 Lee, 2012, Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong, J Gastroenterol Hepatol, 27, 1167, 10.1111/j.1440-1746.2011.07047.x Ruggeri, 2011, The cost-effectiveness of alternative strategies against HBV in Italy, Health Policy, 102, 72, 10.1016/j.healthpol.2010.09.012 Dakin, 2010, Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B, Value Health, 13, 922, 10.1111/j.1524-4733.2010.00782.x Saab, 2010, Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model, Liver Transpl, 16, 748 Yuan, 2008, Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients, J Manag Care Pharm, 14, 21, 10.18553/jmcp.2008.14.1.21 Barros, 2013, Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil, Cost Eff Resour Alloc, 11, 25, 10.1186/1478-7547-11-25 Kuan, 2013, Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine, Vaccine, 31, 4024, 10.1016/j.vaccine.2013.05.014 Wiens, 2013, Economic evaluation of treatments for chronic hepatitis B, Braz J Infect Dis, 17, 418, 10.1016/j.bjid.2012.12.005 Hutton, 2010, Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China, Hepatology, 51, 405, 10.1002/hep.23310 Hutton, 2007, Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B, Ann Intern Med, 147, 460, 10.7326/0003-4819-147-7-200710020-00004 Cucchetti, 2012, Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian liver cancer population, J Hepatol, 56, 1089, 10.1016/j.jhep.2011.11.022 Canavan, 2013, Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK, Dig Dis Sci, 58, 2691, 10.1007/s10620-013-2705-y Landman, 2011, Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?, HPB (Oxford), 13, 783, 10.1111/j.1477-2574.2011.00355.x Vitale, 2010, Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety, Hepatology, 51, 165, 10.1002/hep.23260 2004 Cammà, 2013, Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma, Hepatology, 57, 1046, 10.1002/hep.26221 Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132 Sangro, 2012, Radioembolization for hepatocellular carcinoma, J Hepatol, 56, 464, 10.1016/j.jhep.2011.07.012 Sacco, 2015, Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives, World J Gastroenterol, 21, 6518, 10.3748/wjg.v21.i21.6518 Tarricone, 2016, What type of clinical evidence is needed to assess medical devices?, Eur Respir Rev, 25, 259, 10.1183/16000617.0016-2016 Armeni, 2016, Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation, Int J Cardiol, 209, 153, 10.1016/j.ijcard.2016.01.212 Cappelli, 2014, Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments, J Hepatocell Carcinoma, 1, 163 Bruix, 2011, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 Chaplin S, Taylor M, Lapon J, et al. Economic evaluation of glass yttrium-90 microspheres versus sorafenib for the treatment of advanced hepatocellular carcinoma: cost effectiveness analysis in the United Kingdom. Poster 308. Presented at: The Cardiovascular and Interventional Radiological Society of Europe 2015 Annual Meeting, Lisbon, Portugal, September 26–30, 2015. Yang G, Stemkowski S, Saunders W. A review of propensity score application in healthcare outcome and epidemiology. Available from: http://www.lexjansen.com/pharmasug/2007/pr/pr02.pdf. [Accessed March 10, 2016]. Lencioni, 2014, GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Int J Clin Pract, 68, 609, 10.1111/ijcp.12352